Table 1.

Baseline characteristics of patients with DMARD and biologics used, and of controls. Data are mean ± SD unless otherwise specified.

CharacteristicControls, n = 10DMARD, n = 24Biologics, n = 17p
Age, yrs*55.7 ± 4.559.0 ± 2.253.7 ± 2.70.278
Male/female, n††0:102:224:130.144
RA duration, mos79.5 ± 108.350.1 ± 73.50.643
Anti-CCP, u/ml102.9 ± 19.244.9 ± 45.30.104
RF, u/ml56.3 ± 26.490.0 ± 31.40.672
DAS28-ESR4.5 ± 1.02.9 ± 1.60.002
MTX, mg8.2 ± 1.78.6 ± 1.80.434
  • : Wilcoxon rank sum test.

  • †† : Fisher’s exact test.

  • * : Kruskal-Wallis test. DMARD: disease-modifying antirhreumatic drug; RA: rheumatoid arthritis; DAS-28-ESR: 28-joint Disease Activity Score using erythrocyte sedimentation rate; MTX: methotrexate; anti-CCP: anticyclic citrullinated peptide antibodies; RF: rheumatoid factor.